Published in J Biol Chem on October 26, 2004
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) (2010) 1.80
ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice. J Clin Invest (2012) 1.62
Pin1 regulates centrosome duplication, and its overexpression induces centrosome amplification, chromosome instability, and oncogenesis. Mol Cell Biol (2006) 1.21
P53, cyclin-dependent kinase and abnormal amplification of centrosomes. Biochim Biophys Acta (2008) 1.19
The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2. Oncogene (2010) 1.15
Cdk2 and Cdk4 regulate the centrosome cycle and are critical mediators of centrosome amplification in p53-null cells. Mol Cell Biol (2009) 1.12
Distinct proliferative and transcriptional effects of the D-type cyclins in vivo. Cell Cycle (2008) 1.03
Inhibition of TFII-I-dependent cell cycle regulation by p53. Mol Cell Biol (2005) 1.00
High-resolution mapping identifies a commonly amplified 11q13.3 region containing multiple genes flanked by segmental duplications. Hum Genet (2006) 0.98
Cdk2 plays a critical role in hepatocyte cell cycle progression and survival in the setting of cyclin D1 expression in vivo. Cell Cycle (2009) 0.97
Cortactin expression predicts poor survival in laryngeal carcinoma. Br J Cancer (2008) 0.95
Polycystic kidney disease protein fibrocystin localizes to the mitotic spindle and regulates spindle bipolarity. Hum Mol Genet (2010) 0.95
Restrictions in cell cycle progression of adult vestibular supporting cells in response to ectopic cyclin D1 expression. PLoS One (2011) 0.95
Characteristics of hepatocellular carcinoma in a murine model of alpha-1-antitrypsin deficiency. Hepatol Res (2010) 0.91
The G1 phase Cdks regulate the centrosome cycle and mediate oncogene-dependent centrosome amplification. Cell Div (2011) 0.90
Stromal control of oncogenic traits expressed in response to the overexpression of GLI2, a pleiotropic oncogene. Oncogene (2008) 0.90
Cyclins and cell cycle control in cancer and disease. Genes Cancer (2012) 0.90
Cdk4 and nek2 signal binucleation and centrosome amplification in a her2+ breast cancer model. PLoS One (2013) 0.86
Centrosome amplification in CHO and DT40 cells by inactivation of cyclin-dependent kinases. Cytoskeleton (Hoboken) (2011) 0.84
Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. Br J Cancer (2012) 0.84
E2F activators signal and maintain centrosome amplification in breast cancer cells. Mol Cell Biol (2014) 0.83
The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations. Cancers (Basel) (2014) 0.82
Centrosomes and myeloma; aneuploidy and proliferation. Environ Mol Mutagen (2009) 0.82
Constitutive Cdk2 activity promotes aneuploidy while altering the spindle assembly and tetraploidy checkpoints. J Cell Sci (2013) 0.82
The HTLV-1 tax protein cooperates with phosphorylated CREB, TORC2 and p300 to activate CRE-dependent cyclin D1 transcription. Oncogene (2010) 0.82
Centrosome clustering and cyclin D1 gene amplification in double minutes are common events in chromosomal unstable bladder tumors. BMC Cancer (2010) 0.82
Expression and clinical significance of the Trop-2 gene in advanced non-small cell lung carcinoma. Oncol Lett (2013) 0.81
Diet and body constitution in relation to subgroups of breast cancer defined by tumour grade, proliferation and key cell cycle regulators. Breast Cancer Res (2007) 0.80
Single-cell analysis of ploidy and centrosomes underscores the peculiarity of normal hepatocytes. PLoS One (2011) 0.79
siRNA targeting of Trop2 suppresses the proliferation and invasion of lung adenocarcinoma H460 cells. Exp Ther Med (2015) 0.75
Chromosomal Instability in Gastric Cancer Biology. Neoplasia (2017) 0.75
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
Benign breast disease and the risk of breast cancer. N Engl J Med (2005) 6.84
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol (2006) 4.55
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci U S A (2002) 3.81
Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (2006) 3.40
Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol (2007) 2.58
Centrosome amplification and the development of cancer. Oncogene (2002) 2.51
American College of Medical Genetics and Genomics: standards and guidelines for documenting suspected consanguinity as an incidental finding of genomic testing. Genet Med (2013) 2.50
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol (2010) 2.49
A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of Plk1 in U-2 OS cells. J Biol Chem (2002) 2.40
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood (2009) 2.36
A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res (2006) 2.27
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol (2013) 2.15
Kinesin-like protein CHO1 is required for the formation of midbody matrix and the completion of cytokinesis in mammalian cells. Mol Biol Cell (2002) 2.15
Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. Gynecol Oncol (2009) 1.82
Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer (2007) 1.65
Amplified centrosomes in breast cancer: a potential indicator of tumor aggressiveness. Breast Cancer Res Treat (2002) 1.58
Interaction of Aurora-A and centrosomin at the microtubule-nucleating site in Drosophila and mammalian cells. J Cell Biol (2003) 1.58
Characterization of Cep135, a novel coiled-coil centrosomal protein involved in microtubule organization in mammalian cells. J Cell Biol (2002) 1.56
Age-specific CUGBP1-eIF2 complex increases translation of CCAAT/enhancer-binding protein beta in old liver. J Biol Chem (2006) 1.52
Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats. Proc Natl Acad Sci U S A (2004) 1.50
Glomus tumor of the stomach: cytologic diagnosis by endoscopic ultrasound-guided fine-needle aspiration. Diagn Cytopathol (2003) 1.42
Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol (2008) 1.41
Endoscopic ultrasound-guided fine-needle aspiration cytology diagnosis of solid-pseudopapillary tumor of the pancreas: a rare neoplasm of elusive origin but characteristic cytomorphologic features. Am J Clin Pathol (2004) 1.41
Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer. J Biol Chem (2007) 1.39
A phase II study of amifostine in children with myelodysplastic syndrome: a report from the Children's Oncology Group study (AAML0121). Pediatr Blood Cancer (2011) 1.39
Requirement of hCenexin for proper mitotic functions of polo-like kinase 1 at the centrosomes. Mol Cell Biol (2006) 1.36
Quantitative miRNA expression analysis using fluidigm microfluidics dynamic arrays. BMC Genomics (2011) 1.35
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat (2013) 1.34
Recurrent 10q22-q23 deletions: a genomic disorder on 10q associated with cognitive and behavioral abnormalities. Am J Hum Genet (2007) 1.34
Microarray analysis for constitutional cytogenetic abnormalities. Genet Med (2007) 1.30
Evidence that cyclin D1 mediates both growth and proliferation downstream of TOR in hepatocytes. J Biol Chem (2002) 1.29
Role of the midbody matrix in cytokinesis: RNAi and genetic rescue analysis of the mammalian motor protein CHO1. Mol Biol Cell (2004) 1.29
C/EBPalpha triggers proteasome-dependent degradation of cdk4 during growth arrest. EMBO J (2002) 1.29
Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer. Clin Cancer Res (2005) 1.26
Molecular interactions of Polo-like-kinase 1 with the mitotic kinesin-like protein CHO1/MKLP-1. J Cell Sci (2004) 1.24
Diagnosis of nonprimary pancreatic neoplasms by endoscopic ultrasound-guided fine-needle aspiration. Diagn Cytopathol (2004) 1.24
Ectopic expression of cyclin D3 corrects differentiation of DM1 myoblasts through activation of RNA CUG-binding protein, CUGBP1. Exp Cell Res (2008) 1.23
Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst (2008) 1.22
Cyclin D3 maintains growth-inhibitory activity of C/EBPalpha by stabilizing C/EBPalpha-cdk2 and C/EBPalpha-Brm complexes. Mol Cell Biol (2006) 1.22
Differential control of Eg5-dependent centrosome separation by Plk1 and Cdk1. EMBO J (2011) 1.22
Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer. Breast Cancer Res (2012) 1.21
Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol (2009) 1.21
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol (2011) 1.21
Section E9 of the American College of Medical Genetics technical standards and guidelines: fluorescence in situ hybridization. Genet Med (2011) 1.21
Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood (2010) 1.16
Differential regulation of cyclins D1 and D3 in hepatocyte proliferation. Hepatology (2002) 1.13
Cyclin D1 inhibits hepatic lipogenesis via repression of carbohydrate response element binding protein and hepatocyte nuclear factor 4α. Cell Cycle (2012) 1.11
A Wnt/beta-catenin pathway antagonist Chibby binds Cenexin at the distal end of mother centrioles and functions in primary cilia formation. PLoS One (2012) 1.11
Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood (2012) 1.10
Cisplatin abrogates the geldanamycin-induced heat shock response. Mol Cancer Ther (2008) 1.10
The G-protein regulatory (GPR) motif-containing Leu-Gly-Asn-enriched protein (LGN) and Gialpha3 influence cortical positioning of the mitotic spindle poles at metaphase in symmetrically dividing mammalian cells. Eur J Cell Biol (2006) 1.10
Chronic exposure to lead chromate causes centrosome abnormalities and aneuploidy in human lung cells. Cancer Res (2006) 1.08
Centrosome amplification and the origin of chromosomal instability in breast cancer. J Mammary Gland Biol Neoplasia (2004) 1.08
Hematopoietic growth factors--use in normal blood and stem cell donors: clinical and ethical issues. Transfusion (2008) 1.06
Aurora A, centrosome structure, and the centrosome cycle. Environ Mol Mutagen (2009) 1.05
Genomewide microRNA down-regulation as a negative feedback mechanism in the early phases of liver regeneration. Hepatology (2011) 1.05
Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Breast Cancer Res (2011) 1.05
Tissue composition of mammographically dense and non-dense breast tissue. Breast Cancer Res Treat (2011) 1.05
Growth hormone corrects proliferation and transcription of phosphoenolpyruvate carboxykinase in livers of old mice via elimination of CCAAT/enhancer-binding protein alpha-Brm complex. J Biol Chem (2006) 1.03
Distinct proliferative and transcriptional effects of the D-type cyclins in vivo. Cell Cycle (2008) 1.03
Akt-mediated liver growth promotes induction of cyclin E through a novel translational mechanism and a p21-mediated cell cycle arrest. J Biol Chem (2007) 1.02
Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol Cancer Ther (2008) 1.01
Multivitamin and alcohol intake and folate receptor alpha expression in ovarian cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.00
Endoscopic ultrasound-guided fine-needle aspiration findings of gastrointestinal leiomyomas and gastrointestinal stromal tumors. Am J Clin Pathol (2003) 0.99
Diagnosis of myelodysplastic syndrome among a cohort of 119 patients with fanconi anemia: morphologic and cytogenetic characteristics. Am J Clin Pathol (2010) 0.99
Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study. Cancer Res (2008) 0.98
Intraductal papillary-mucinous neoplasm of the pancreas. The findings and limitations of cytologic samples obtained by endoscopic ultrasound-guided fine-needle aspiration. Am J Clin Pathol (2003) 0.98
Aurora a and B overexpression and centrosome amplification in early estrogen-induced tumor foci in the Syrian hamster kidney: implications for chromosomal instability, aneuploidy, and neoplasia. Cancer Res (2007) 0.97
Genetic endothelial systems biology of sickle stroke risk. Blood (2007) 0.97
Cdk2 plays a critical role in hepatocyte cell cycle progression and survival in the setting of cyclin D1 expression in vivo. Cell Cycle (2009) 0.97
Haematopoietic cell transplantation for acute leukaemia and advanced myelodysplastic syndrome in Fanconi anaemia. Br J Haematol (2013) 0.96
Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia. Genes Chromosomes Cancer (2007) 0.96
S6 kinase 1 is required for rapamycin-sensitive liver proliferation after mouse hepatectomy. J Clin Invest (2011) 0.96
The cytoskeleton differentially localizes the early growth response gene-1 protein in cancer and benign cells of the prostate. Mol Cancer Res (2004) 0.96
Network-based approach identified cell cycle genes as predictor of overall survival in lung adenocarcinoma patients. Lung Cancer (2013) 0.96
Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance. Clin Cancer Res (2008) 0.95
Restrictions in cell cycle progression of adult vestibular supporting cells in response to ectopic cyclin D1 expression. PLoS One (2011) 0.95
Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437. Clin Cancer Res (2011) 0.95
Aromatase immunoreactivity is increased in mammographically dense regions of the breast. Breast Cancer Res Treat (2010) 0.94
Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. Am J Hematol (2007) 0.94
High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group. Br J Haematol (2013) 0.93
Quantifying insulin receptor isoform expression in FFPE breast tumors. Growth Horm IGF Res (2012) 0.93
Amino acids regulate hepatocyte proliferation through modulation of cyclin D1 expression. J Biol Chem (2003) 0.93
Activation of the transcription factor GLI1 by WNT signaling underlies the role of SULFATASE 2 as a regulator of tissue regeneration. J Biol Chem (2013) 0.93
Interaction of Cep135 with a p50 dynactin subunit in mammalian centrosomes. Cell Motil Cytoskeleton (2004) 0.92
Rapamycin-sensitive induction of eukaryotic initiation factor 4F in regenerating mouse liver. Hepatology (2004) 0.92
Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer. Sci Transl Med (2013) 0.92